Women & HIV Back grey_arrow_rt.gif
 
AIDS is the leading cause of death among African American and Hispanic women ages 25-44 in the US. African American and Hispanic women accounted for 76% of new AIDS cases among women reported in 1996 in the US. Women are one of the fastest growing groups of new AIDS cases, accounting for 20% of newly reported cases in the US and 42% of new cases worldwide. In clinical research on potential treatments, only 12% of research participants are female. Women are 33% more likely to die than men because treatment begins so much later, if at all.
 
null.gif
 
 
  1. Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus - (09/12/22)
     
  2. Hormone therapy and fractures [VMS] in postmenopausal women - (09/12/22)
     
  3. Menopausal Hormone Therapy and Subclinical Cardiovascular Disease in Women With and Without Human Immunodeficiency Virus - (09/12/22)
     
  4. CROI: Choice and Adherence to Dapivirine Ring or Oral PrEP by Young African Women in REACH (02/23/22)
     
  5. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  6. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  7. CROI: Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF: the randomized IMPAACT 2010 trial - (02/22/22)
     
  8. CROI: HBIg-Free Strategy Prevents Vertical HBV Transmission-If Mothers Start TDF Soon Enough - Mark Mascolini (02/22/22)
     
  9. CROI: PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING (02/16/22)
     
  10. Undertreated midlife symptoms for women living with HIV linked to lack of menopause discussions with providers - menopausal hormone therapy under-utilized - (02/07/22)
     
  11. Menopause Is Associated With Immune Activation in Women With HIV - (01/19/22)
     
  12. Women with HIV Have More Comorbidities, Worse Physical Function, & Inflammation - (01/07/22)
     
  13. Faces of Frailty [women] in Aging with HIV Infection - (01/07/22)
     
  14. Focus Groups - 2015 - WIHS-Wash DC - Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts - (10/17/21)
     
  15. Black Cisgender Women's PrEP Knowledge, Attitudes, Preferences, and Experience in Chicago - (10/17/21)
     
  16. "PrEP"ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women - (10/17/21)
     
  17. Co-located HIV Services Can Help Women Who Inject Drugs Access PrEP, Study Shows - (10/17/21)
     
  18. Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States - (10/17/21)
     
  19. ART & Cervical Cancer Women with HIV Risk - (07/14/21)
     
  20. 2 New studies: Diabetes-Depression-Women & High Suicide Rates PLWH - (07/09/21)
     
  21. CROI: Women & HIV at CROI - (03/28/21)
     
  22. CROI: SEX DIFFERENCES IN DIABETES PREVELANCE AMONG PERSONS WITH HIV IN THE UNITED STATES...40% of HIV+ Women >65 have diabetes. - (03/19/21)
     
  23. HIV+ Women Have Higher Burden of Comorbidities vs HIV- Women / Accelerated-Earlier by 10 Years - (03/02/21)
     
  24. HIV+ Women & MSM: aging & other issues - (02/22/21)
     
  25. Changing epidemiology, implications, and recommendations for Hepatitis C in Women of Childbearing Age and During Pregnancy - (12/15/20)
     
  26. Disparate Impact of HIV/Aging on women - (06/30/20)
     
  27. HIV Neuropathy: Women & Men/Prevalence-Risk Factors - (06/30/20)
     
  28. HCV & Women - several key reports - (03/10/15)
     
  29. CROI: HIV Infection and the Risk of Cardiovascular Disease in Women - (03/26/14)
     
  30. CROI: Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis C Viremia in HIV Infection: A Women's Interagency HIV Study - (03/15/13)
     
  31. CROI: The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/15/13)
     
  32. The Association of Race, Sociodemographic, and Behavioral Characteristics With Response to Highly Active Antiretroviral Therapy in Women: 'depression, black/latino women, HAART discontinuation, higher death rates, drug use all related' - (04/03/12)
     
  33. Women & HIV: Medical Care for Menopausal and Older Women With HIV Infection - (03/29/12)
     
  34. Women & HIV: Testosterone & HIV+ Women - adverse events - (03/29/12)
     
  35. Women & HIV: Gender Gap in CVD: The Epidemiology of Cardiovascular Disease in Postmenopausal Women-see article below - (03/29/12)
     
  36. Women & HIV: Sex Differences in the Pharmacologic Effects of Antiretroviral Drugs: Potential Roles of Drug Transporters and Phase 1 and 2 Metabolizing Enzymes - (03/29/12)
     
  37. Women & HIV: Women & HIV: Black Women in USA; trauma; childhood sex abuse; heart disease in HIV+ women - (03/29/12)
     
  38. Women & HIV: Heart Disease & Women HIV+, inflammation: Obesity and Dyslipidemia in Behaviorally HIV-Infected Young Women: Adolescent Trials Network Study 021 - (03/29/12)
     
  39. Women & HIV: Gender differences in the treatment of HIV infection - review - (03/29/12)
     
  40. 2nd Intrntnl Wrkshp HIV & Women: Sexual Abuse as Child Raises Heart Disease Risk in HIV-Positive Women - (01/11/12)
     
  41. 2nd Intrntnl Wrkshp HIV & Women: Gardasil Study - Most Young HIV-Positive Women Still Negative for Key HPV Genotypes (01/11/12)
     
  42. 2nd Intrntnl Wrkshp HIV & Women: Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Naïve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials (01/11/12)
     
  43. 2nd Intrntnl Wrkshp HIV & Women: Lopinavir Side Effects Differ by Weight in Women, But RNA Response Does Not (01/11/12)
     
  44. 2nd Intrntnl Wrkshp HIV & Women: Differences Between Women and Men on Rilpivirine vs Efavirenz for 96 Weeks (01/11/12)
     
  45. 2nd Intrntnl Wrkshp HIV & Women: Hormonal Contraceptives Tied to Non-AIDS Disease or Death in HIV+ US Women: 'doubles Non-AIDS Risks' (01/11/12)
     
  46. 2nd Intrntnl Wrkshp HIV & Women: Treatment Access Biggest Trial Plus in Survey of Women/Minority GRACE Study (01/11/12)
     
  47. 2nd Intrntnl Wrkshp HIV & Women: One Third of HIV+ South Carolina Women Not Getting Regular Pap Test (01/10/12)
     
  48. 2nd Intrntnl Wrkshp HIV & Women: US Girls With HIV Have Doubled Rate of Anal HPV and Related Conditions (01/10/12)
     
  49. 2nd Intrntnl Wrkshp HIV & Women: More Depression in HIV+ Women Than Men, Regardless of ART, in 15-Country Study (01/10/12)
     
  50. 2nd Intrntnl Wrkshp HIV & Women: Cervical Lesion Excision Does Not Boost Genital HIV Shedding in Small Cohort (01/10/12)
     
  51. Viramune HIV Infant Prophylaxis Safe: "Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial" - (01/02/12)
     
  52. 1st Intrnl Wrkshp HIV & Women: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/ritonavir (ATV/r) Once Daily Given in Combination With Twice Daily AZT/3TC During Pregnancy: Results of Study AI424182 - (01/19/11)
     
  53. 1st Intrnl Wrkshp HIV & Women: Reyataz During Pregnancy - written by Mark Mascolini - (01/16/11)
     
  54. 1st Intrnl Wrkshp HIV & Women: Efficacy, Safety and Tolerability of Lopinavir/ritonavir (LPV/r) in HIV-Infected Women: Results of a Meta-Analysis of 7 Prospective, Randomized Clinical Trials (RCTs) Through 48 Weeks - (01/15/11)
     
  55. 1st Intrnl Wrkshp HIV & Women: RNA and CD4 Response to Lopinavir Similar in Women and Men in 7-Trial Analysis - written by Mark Mascolini - (01/14/11)
     
  56. 1st Intrnl Wrkshp HIV & Women: Sex Transmission: Defining Mucosal Immune Factors That Stymie HIV Remains Tough Job - written by Mark Mascolini - (01/14/11)
     
  57. 1st Intrnl Wrkshp HIV & Women: Registry Sees No Increased Overall Birth Defect Risk With First-Trimester Antiretrovirals - written by Mark Mascolini - (01/11/11)
     
  58. 1st Intrnl Wrkshp HIV & Women: Low Bone Density Not Linked to Lipodystrophy in Small Group of Canadian Women (see report from Workshop below) - written by Mark Mascolini - (01/11/11)
     
  59. 1st Intrnl Wrkshp HIV & Women: Trough Levels of Four Key Antiretroviral Higher in Women Than General Population - written by Mark Mascolini - (01/11/11)
     
  60. 1st Intrnl Wrkshp HIV & Women: Women Report Better Quality-of-Life Gains Than Men in GRACE Trial of Darunavir - written by Mark Mascolini - (01/11/11)
     
  61. 1st Intrnl Wrkshp HIV & Women: Gender Not Linked to Liver Disease Progression in HIV/HCV+ Canadians - written by Mark Mascolini - (01/11/11)
     
  62. 1st Intrnl Wrkshp HIV & Women: Association of Sex and Race with Health-related Quality of Life in Patients Treated with Darunavir/ritonavir-based Therapy in the GRACE (Gender, Race And Clinical Experience) Trial - (01/12/11)
     
  63. 1st Intrnl Wrkshp HIV & Women: Microbicide Disclosure to Partners Did & Results of CAPRISA 004 - written by Mark Mascolini - (01/11/11)
     
  64. 1st Intrnl Wrkshp HIV & Women: Striking Regional Antiretroviral Response Differences Found in Canadian Women - written by Mark Mascolini - (01/11/11)
     
  65. 1st Intrnl Wrkshp HIV & Women: Violence Linked to Substance Use and Mental Health in BC Women With HIV - written by Mark Mascolini - (01/11/11)
     
  66. 1st Intrnl Wrkshp HIV & Women: Switch to Opt-Out HIV Screening Promotes Testing in Women of Washington, DC - written by Mark Mascolini - (01/11/11)
     
  67. 1st Intrnl Wrkshp HIV & Women: Half of HIV-Positive Women in Ontario Survey Have Unintended Pregnancies - written by Mark Mascolini - (01/11/11)
     
  68. 1st Intrnl Wrkshp HIV & Women: ART Response and Rebound Worse in Female IDUs Than Male IDUs - written by Mark Mascolini - (01/11/11)
     
  69. Population Pharmacokinetics of Nevirapine in HIV-1-Infected Pregnant Women and Their Neonates - published pdf attached - (12/30/10)
     
  70. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  71. The Steady State Pharmacokinetics (PK) of Atazanavir/Ritonavir (ATV/RTV) During Pregnancy in HIV+ Women - (12/22/10)
     
  72. 10th Congress Drug Therapy HIV: Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10)
     
  73. Patterns of neonatal bilirubin following atazanavir/ritonavir (ATV/r) treatment of mothers during pregnancy: clinical and pharmacogenetic factors identified in study AI424182 - (12/19/10)
     
  74. ICAAC: Raltegravir Pharmacokinetics during Pregnancy (09/16/10)
     
  75. IAC: High Prevalence of Bone Demineralization in a Cohort of HIV-Infected Postmenopausal Women - (08/06/10)
     
  76. CROI: T-Cell Activation and Senescence Linked to Carotid Lesions in HIV+ Women - written by Mark Mascolini - (02/21/10)
     
  77. CROI: Raltegravir Concentrations in the Cervicovaginal Compartment Exceed the Median Inhibitory Concentration in HIV-1-infected Women Treated with a Raltegravir-containing Regimen: DIVA 01 Study - (02/22/10)
     
  78. The rate of mother-to-child HIV transmission among infants is 23 times higher for blacks than whites, the CDC reported. - (02/05/10)
     
  79. Bone Loss in HIV+ Premenopausal Women & Fracture Risk - (02/04/10)
     
  80. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women (and men) - (01/29/09)
     
  81. Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection - (01/19/09)
     
  82. Gender & Racial Differences in Discontinuation of HAART JAIDS Nov 2009 - (12/23/09)
     
  83. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
     
  84. Tenofovir Gel & Tablets PrEP Study: Clinical Trial of Antiretroviral-based HIV Prevention Strategies for Women Now Under Way (study in 5,000 women) - (09/21/09)
     
  85. Low Vitamin D Levels Increased Risk for HIV MTCT: Perinatal Outcomes, Including Mother-to-Child Transmission of HIV, and Child Mortality and Their Association with Maternal Vitamin D Status in Tanzania - (08/03/09)
     
  86. Mild Glucose Intolerance In Pregnancy May Be Associated With Cardiovascular Risk - (08/26/09)
     
  87. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women - it accumulated at high levels quickly in CVF & vaginal tissue - (08/04/09)
     
  88. 5th IAS: The Safety, Efficacy, and Steady State Pharmacokinetics of Atazanavir/Ritonavir (ATV/r) Once Daily During Pregnancy: Results of Study AI424182 - (07/30/09)
     
  89. 5th IAS: Triple Antiretrovirals Cut Breastfeeding HIV Transmission Rate Below 1% - written by Mark Mascolini - (07/29/09)
     
  90. 5th IAS: Blacks and Women Have Worse Virologic Response in Trial of ABC/3TC vs TDF/FTC - written by Mark Mascolini - (07/21/09)
     
  91. 5th IAS: GRACE: New HIV Study Shows that Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies - (07/21/09)
     
  92. 5th IAS: African-American Women Need Services is Highlighted in: GRACE (Gender, Race And Clinical Experience): 48-Week Results of Darunavir/r-based Therapy in the Largest Trial in North America to Focus on Treatment-experienced Women - (07/21/09)
     
  93. 5th IAS: Differences in Virologic Response Among African Americans and Females Regardless of Therapy in the HEAT Study: African-Americans Have Lower Viral Response Rates - (07/21/09)
     
  94. Mortality in WIHS, Women of Color: non-AIDS Events, Viral Replication & low CD4, Depression, Violence, HCV/HBV, Drug Use: Federal AIDS funding neglects inner-city women of color - (07/17/09)
     
  95. Lopinavir/Ritonavir in Pregnancy - (07/16/09)
     
  96. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women - A preliminary study - (07/10/09)
     
  97. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance - (04/20/09)
     
  98. Routine HIV testing recommended for women - (04/08/09)
     
  99. ISHLVD: Use of Tenofovir Disoproxil Fumarate (TDF) in Pregnancy: Findings from the Antiretroviral Pregnancy Registry (APR) - (03/25/09)
     
  100. HIV-Specific IgG in Cervicovaginal Secretions of Exposed HIV-Uninfected Female Sexual Partners of HIV-Infected Men - (03/19/09)
     
  101. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants: ART before age 3 months dramatically reduces AIDS/death - (03/19/09)
     
  102. CROI: Microbicide PRO 2000/0.5% Gel Shows Promise - (03/02/09)
     
  103. CROI: Cervicovaginal Shedding of HIV-1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota - (02/26/09)
     
  104. CROI: Single Dose Tenofovir Disoproxil Fumarate (TDF) with and without Emtricitabine (FTC) in HIV-1 Infected Pregnant Women and Their Infants: Pharmacokinetics (PK) and Safety - - (02/24/09)
     
  105. Risk Factors for Early and Late Transmission of HIV via breast-feeding among Infants Born to HIV-Infected Women in a Randomized Clinical Trial in Botswana - (01/17/09)
     
  106. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women: "Our findings show that the prevalence of AIN among HIV-infected women is high and significantly increased above a comparison group of HIV-uninfected women." - (12/15/08)
     
  107. HIV CRISIS: AIDS is the leading cause of death for African-American women ages 25-34 today - (10/31/08)
     
  108. HIV Doctors May Treat All Infected, Adding Thousands: When To Start HAART Debate - (10/31/08)
     
  109. ICAAC: Black Women in US Less Likely to Get Antiretrovirals, Regardless of Insurance - Written by Mark Mascolini - (10/27/08)
     
  110. ICAAC: Doubled Risk of Failure After 1 Year Under 50 Copies in Women and Steady Blippers - Written by Mark Mascolini - (10/30/08)
     
  111. ICAAC: Half of Black US Women Switch HIV Clinicians Because of Communication Problems - Written by Mark Mascolini - (10/27/08)
     
  112. Home use of vegetable oils, markers of systemic inflammation, and endothelial dysfunction among women - (10/08/08)
     
  113. Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) -
     
  114. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors - (10/08/08)
     
  115. Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) -
     
  116. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle - (09/23/08)
     
  117. Breast milk purged of HIV virus by Nipple Shield+Chemical - (09/22/08)
     
  118. HAART, Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire - (09/18/08)
     
  119. Analysis of Nevirapine (NVP) Resistance in Ugandan Infants Who Were HIV Infected Despite Receiving Single-Dose (SD) NVP versus SD NVP Plus Daily NVP Up to 6 Weeks of Age to Prevent HIV Vertical Transmission - (09/8/08)
     
  120. IAS: Clinicians Fail to Routinely Provide Reproductive Counseling to HIV-Infected Women in the United States - (08/27/08) -
     
  121. IAS: Societal Stigma of Pregnant HIV-Infected Women in the United States - (08/27/08) -
     
  122. IAS: Women's Rights Equals Women's Lives - from Mexico - (08/19/08) -
     
  123. IAS: HIV Crosses the Gender Divide - (08/19/08) -
     
  124. Enhancement of HIV Infection by Cellulose Sulfate - (07/31/08)
     
  125. Lack of Effectiveness of Microbicide Cellulose Sulfate Gel for the Prevention of Vaginal HIV Transmission - (07/31/08)
     
  126. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort - (07/29/08)
     
  127. Extended nevirapine prophylaxis to prevent HIV transmission - (07/29/08)
     
  128. Viagra for Women with Antidepressant-Associated Sex Dysfunction - (07/25/08)
     
  129. Effects of Early, Abrupt Weaning for HIV-free Survival of Children in Zambia - (06/11/08)
     
  130. Breast-Feeding, Antiretroviral Prophylaxis, and HIV - (06/11/08)
     
  131. HAART Can Eliminate HIV Mother-To-Child Transmission (MTCT). Properly Timed Effective Use of HAART Can Prevent MTCT - (05/07/08)
     
  132. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women - (05/01/08)
     
  133. Pregnancy May Not Protect Against HIV Disease Progression - (03/25/08)
     
  134. CROI: Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women - (03/07/08)
     
  135. MOST WOMEN WITH HIV AND THEIR HEALTH CARE PROVIDERS HAVE NOT DISCUSSED HOW HIV MIGHT AFFECT THEM DIFFERENTLY THAN MEN - (12/28/07)
     
  136. Higher Vitamin D Supplements Advised for Older Black Women - (12/11/07)
     
  137. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine (09/26/07)
     
  138. Prevalence and Long-Term Effects of Occult Hepatitis B Virus Infection in HIV-Infected Women - (08/17/07)
     
  139. Diaphragm and lubricant gel + Condom for prevention of HIV acquisition in southern African women: a randomised controlled trial - (07/19/07)
     
  140. U.S. NIH Funded Trial of VivaGel in Sexually Active Young Women Commences - (07/17/07)
     
  141. "He Won't Use Condoms": HIV-Infected Women's Struggles in Primary Relationships With Serodiscordant Partners - (07/02/07)
     
  142. Effects of Weight, Body Composition, and Testosterone on Bone Mineral Density in HIV-Infected Women - (06/20/07)
     
  143. Association of Serum Lipid Levels With HIV Serostatus, Specific Antiretroviral Agents, and Treatment Regimens in WIHS (Women) - (05/22/07)
     
  144. Hysterectomy Among Women With HIV: Indications and Incidence - (05/22/07)
     
  145. Resistance to Antiretroviral Drugs: A Threat to the Prevention and Treatment of Pediatric HIV Infection EDITORIAL COMMENTARY - (05/03/07)
     
  146. Early Archiving and Predominance of NNRTI-Resistant HIV-1 among Recently Infected Infants Born in the United States - (05/03/07)
     
  147. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children - (04/29/07)
     
  148. Assessment of Birth Defects According to Maternal Therapy Among Infants in the Women and Infants Transmission Study (WITS) - (04/03/07)
     
  149. Use of ART in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis - (04/03/07)
     
  150. Dose-Ranging Phase 1 Study of TMC120, a Promising Vaginal Microbicide, in HIV-Negative and HIV-Positive Female Volunteers - (02/23/07)
     
  151. Safety of nevirapine in pregnancy - (01/19/07)
     
  152. Extra-Hepatic HCV in HIV+ Women: Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Antibody HCV-Positive/HIV-Infected Women - (01/03/07)
     
  153. Cervical Shedding of HIV-1 RNA Among Women With Low Levels of Viremia While Receiving HAART - (01/04/07)
     
  154. Discontinuation of ART Postpartum: No Evidence for Altered Viral Set Point [Letters to the Editor] - (01/04/07)
     
  155. Human Papilloma Virus (HPV) Infection of the Anus Is More Prevalent and Diverse than Cervical HPV Infection among HIV-Infected Women in the SUN Study - (12/08/06)
     
  156. Natural Pregnancies in HIV-Serodiscordant Couples Receiving Successful Antiretroviral Therapy - (12/08/06)
     
  157. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States / Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy - (10/20/06)
     
  158. ICAAC: Tenofovir and Lopinavir Levels in Pregnant Women and Infants - Written for NATAP by Mark Mascolini - (10/16/06)
     
  159. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities - (09/12/06)
     
  160. Longitudinal Analysis of Bone Density in HIV-Infected Women - (09/06/06)
     
  161. The mother-to-child HIV transmission epidemic in Europe (Ukraine & Eastern Europe): evolving in the East and established in the West - (07/17/06)
     
  162. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women - (05/17/06)
     
  163. HAART & Fetal death/Pre-eclampsia - (04/24/06)
     
  164. Antioxidant supplementation in pre-eclampsia: Commentary - (04/24/06)
     
  165. Heart Disease Prevention in Women (men too) - (04/24/06)
     
  166. Errors in Celia Farber's March 2006 article in Harper's Magazine - (03/15/06)
     
  167. HCV Mother-to-child transmission: HAART May Reduce HCV MTC; C-Section Did Not Reduce MTC - (03/15/06)
     
  168. HIV-Positive Latina Immigrants in California - (02/28/06)
     
  169. CROI: Rapid Emergence of Drug-resistant SIV in Tenofovir-treated Macaques: Implications for Tenofovir Chemoprophylaxis against HIV (02/27/06)
     
  170. Tenofovir may be safe as vaginal HIV microbicide - (02/24/06)
     
  171. CROI: Tenofovir Achieves High Levels in the Genital tract of Men & Women and Reduces HIV RNA in Genital Tract of Men & Women (02/13/06)
     
  172. WISE Study of Women and Heart Disease Yields Important Findings on Frequently Undiagnosed Coronary Syndrome - (01/31/06)
     
  173. Vaccination of Infants of Hepatitis B Mothers - (01/30/06)
     
  174. HIV Sexual Transmission Risks: during acute & chronic with <400 c/ml - (01/27/06)
     
  175. Experimental vaginal gel inhibits HIV and HSV - (01/25/06)
     
  176. PRO 2000 Gel Inhibits HIV and Herpes Simplex Virus Infection Following Vaginal Application: A Double-Blind Placebo-Controlled Trial - (01/05/06)
     
  177. Microbicides to Prevent HIV Transmission: Overcoming Obstacles to Chemical Barrier Protection - (01/05/06)
     
  178. HCV Transmission Risks from Mother-To-Child up to 6.2% - (11/09/05)
     
  179. Vaginal Microbicide Gel Phase III Study Enrolled - (10/28/05)
     
  180. Vaginal Gel Trials Start in South Africa - (10/28/05)
     
  181. Microbicide Study in Women Begins - (10/25/05)
     
  182. Presence of Hepatitis C Virus (HCV) RNA in the Genital Tracts of HCV/HIV-1-Coinfected Women - (10/05/05)
     
  183. 6.3% Prevalence of hepatitis B and C in pregnant women who are infected with HIV - (09/21/05)
     
  184. Protease Inhibitor Use in 233 Pregnancies - (09/14/05)
     
  185. Therapy-associated severe hyperlactatemia rare in HIV patients - (09/02/05)
     
  186. 2 Articles on Pregnancy in HIV: HAART & Congential Abnormalities; Mitochondrial Toxicity in Uninfected Newborns - (09/02/05)
     
  187. IAS: Atazanavir Use in Pregnancy (08/05/05)
     
  188. Low-dose oral contraceptives increase cardiovascular disease risk - (07/13/05)
     
  189. High Rate of Recurrence of Cervical Intraepithelial Neoplasia After Surgery in HIV-Positive Women - (07/20/05)
     
  190. Safety, Acceptability, and Potential Efficacy of a Topical Penile Microbicide Wipe - (07/08/05)
     
  191. HIV-Positive U.S. Women More Concentrated in South, Among Minorities, CDC Says at HIV Prevention Conference in Atlanta - (06/16/05)
     
  192. Early antiretroviral therapy decreases progression of perinatal HIV - (05/13/05)
     
  193. EASL: HIV & High HCV Viral load Increased HCV Perinatal Transmission (05/05/05)
     
  194. Body Changes in Women Associated with Heart Disease Risk: "Increased Cardiovascular Disease Risk Indices in HIV-Infected Women" - (05/04/05)
     
  195. HIV load and CD4+ cell count affect HPV detection in HIV-infected women - (04/22/05)
     
  196. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy - (04/12/05)
     
  197. 25% of Women in WIHS Stop HAART for at least 6 Months - (04/01/05)
     
  198. Gender Affect in HIV & HAART - (04/01/05)
     
  199. "Women At Risk: The Health of Women in New York City" Report Released - (04/01/05)
     
  200. CROI: Prevention of mother-to-child transmission and nevirapine resistance - Reported for NATAP by David Margolis, MD - (03/09/04)
     
  201. Herpes Zoster in Women With and at Risk for HIV: Data From the Women's Interagency HIV Study - (02/07/05)
     
  202. Fat Distribution in HIV-Infected Women in the United States: DEXA Substudy in the Women's Interagency HIV Study - (12/21/04)
     
  203. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with HAART in Europe - (12/15/04)
     
  204. Protease Inhibitor and NNRTI Concentrations in the Genital Tract of HIV+ Women - (12/06/04)
     
  205. HIV-Associated Anal Cancer: Has Highly Active Antiretroviral Therapy Reduced the Incidence or Improved the Outcome? - (12/06/04)
     
  206. High Prevalence of HBV in HIV+ & HIV- Women -WIHS - (10/21/04)
     
  207. HAART Resolves Life-Threatening Anemia in Women - (10/05/04)
     
  208. Women & HIV-CDC Updates HIV/AIDS Surveillance Among Women in US - (09/27/04)
     
  209. Glaxo AIDS Drugs to Be Tested In Topical Form, as Microbicide - (09/24/04)
     
  210. Depression & No HAART Increases Risk for AIDS-Death Among HIV+ Women in WIHS - (09/21/04)
     
  211. Nelfinavir Plasma Concentrations Are Low during Pregnancy - (09/07/04)
     
  212. Safety and tolerability of vaginal tenofovir gel (TFV) in HIV-uninfected and HIV-infected women (HPTN 050) - (08/30/04)
     
  213. Metabolic complications of HIV therapy in children: lipodystrophy, dyslipidemias, insulin resistance, bones disease, avascular necrosis, mitochondrial toxicity - (08/20/04)
     
  214. XV International AIDS Conference in Bangkok: IMPACT OF HCV VIREMIA ON HIV DISEASE PROGRESSION IN WOMEN: HCV INCREASES RISK FOR AIDS (WIHS) - (07/22/04)
     
  215. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe - (07/01/04)
     
  216. Cancer Risk Among Participants in the Women's Interagency HIV Study - (06/30/04)
     
  217. Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery - (06/28/04)
     
  218. Persistance of HPV in HIV+ Adolescent Girls - (06/28/04)
     
  219. Maternal Toxicity With Continuous Nevirapine in Pregnancy: Results From PACTG 1022 - (06/22/04)
     
  220. Contraceptive Use in HIV-Positive Women - (06/07/04)
     
  221. NRTIs and Intracellular Activity and Toxicities for Women, Advanced HIV & Hepatitis - (05/17/04)
     
  222. Smoking Increases Risk for Cervical Cancer in HIV+ - (05/10/04)
     
  223. Famcyclovir for Herpes Simplex Virus Shedding in Women - (05/10/04)
     
  224. Gender, Pregnancy, and PKs - (05/10/04)
     
  225. Recommendations for the Nonclinical Development of Topical Microbicides for Prevention of HIV Transmission: An Update - (05/04/04)
     
  226. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir - (05/03/04)
     
  227. Women with HIV can benefit from testosterone treatment - (04/27/04)
     
  228. Antiretroviral Therapy and the Clinical Evolution of Human Papillomavirus Associated Genital Lesions in HIV-Positive Women - (04/05/04)
     
  229. HIV in Semen, Effect of HAART, Sexual Transmission of HIV, & Relevance in Getting Pregnant - (03/31/04)
     
  230. Reduced bone density in HIV-infected women - (03/10/04)
     
  231. Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study - (02/23/04)
     
  232. CROI: HIV Microbocides at the 11th Retrovirus Conference - (02/23/04)
     
  233. The effect of hormonal contraception on genital tract shedding of HIV-1 - (02/06/04)
     
  234. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program in WIHS Study - (01/26/04)
     
  235. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes - (01/05/04)
     
  236. AZT Monotherapy To Prevent Perinatal Transmission - (01/05/04)
     
  237. Increased Risk for Fat Loss in HIV+ Women Observed in WIHS Study - (12/08/03)
     
  238. HIV viral load in Blood may not predict HIV shedding in vaginal secretions - (11/05/03)
     
  239. HIV viral load in Blood may not predict HIV shedding in vaginal secretions - (11/05/03)
     
  240. EACS - HCV Sexual Transmission --MSM & Heterosexual - (11/04/03)
     
  241. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals - (10/8/03)
     
  242. Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women - (9/30/03)
     
  243. Microbicides: STD Protection With or Without Contraception - (8/18/03)
     
  244. Background Information Microbicide Drug Candidates Including Cyanovirin-N To Prevent Anal & Vaginal HIV Transmission - (8/18/03)
     
  245. FDA Hearing on Microbicides to Prevent HIV Transmission to Women: trial considerations - (8/18/03)
     
  246. Sperm washing in the UK: evidence of safety and efficacy - (4/30/03)
     
  247. High Rates of Viral Infections & HCV and For Risk Factors Among HIV-Infected and High-Risk HIV-Uninfected Women - (4/21/03)
     
  248. Protease Inhibitor Use and the Incidence of Diabetes Mellitus in a Large Cohort of HIV-Infected Women - (4/2/03)
     
  249. Prevalence of Genotypic Drug Resistance Among a Cohort of HIV-Infected Newborns: suggesting resistance testing in newborns - (4/2/03)
     
  250. HCV in Semen - (3/26/03)
     
  251. Night Before or After Pill To Prevent HIV Transmission - (3/17/03)
     
  252. Retro - Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study - (3/10/03)
     
  253. Resistance Testing Recommended For Pregnant Women: Nonnucleoside Reverse Transcriptase Inhibitor Resistance Observed Among Antiretroviral-Naive HIV-Positive Pregnant Women - (3/6/03)
     
  254. Perinatal Hepatitis C Virus Transmission: Role of Human Immunodeficiency Virus Infection and Injection Drug Use - Gregory L. Armstrong, Joseph F. Perz, and Miriam J. Alter Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia - (2/28/03)
     
  255. Impact of Antiretroviral Therapy and Changes in Virus Load on Human Immunodeficiency Virus (HIV)Specific T Cell Responses in Primary HIV Infection - (2/26/03)
     
  256. Tale of Two Epidemics: The Continuing Challenge of Preventing Mother-to-Child Transmission of Human Immunodeficiency Virus - (2/26/03)
     
  257. Retroconference Update: HIV and Women Written for NATAP by Judith Aberg, MD, Washington University, St Louis, MO, ACTG - (2/24/03)
     
  258. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women - (12/02/02)
     
  259. Switch Study in Children to Efavirenz from Protease Inhibitor - (10/8/02)
     
  260. Viral load in HCV RNA-positive pregnant women - (9/18/02)
     
  261. Hep C & Pregnancy: risks for transmission - (9/18/02)
     
  262. Does Patient Gender Affect Human Immunodeficiency Virus Levels? - (9/13/02)
     
  263. Women With Impaired Glucose Tolerance During Pregnancy Have Significantly Poor Pregnancy Outcomes - (8/27/02)
     
  264. Depression & Anxiety Can Occur in Diabetics and Their Partners, Particularly Women - (8/27/02)
     
  265. Sperm Washing for Pregnancy in HIV - (8/27/02)
     
  266. Barcelona - Anal Sex Increases Risk For Heterosexual HIV Transmission - (7/17/02)
     
  267. Kaletra in Women - (7/12/02)
     
  268. Recurrence rate of cervical dysplasia high in HIV-positive women - 06/12/02
     
  269. Women and HCV - (06/03/02)
     
  270. GILEAD ANNOUNCES INITIATION OF NIH-SPONSORED PHASE I TRIAL TO EVALUATE TENOFOVIR TOPICAL GEL AS PREVENTIVE FOR VAGINAL TRANSMISSION OF HIV - (05/22/02)
     
  271. Women with HIV: More conference time Written for NATAP by Judith Aberg, MD, Washington University, Director of HIV Clinic, St Louis - (03/19/02)
     
  272. Maternal - Fetal Transmission at Retrovirus Written by Danielle Milano, MD, Boriken Family Health Services, New York - (03/18/02)
     
  273. HIV and Women at Retrovirus Written for NATAP by Danielle Milano, MD, Boriken Family Health Services, NYC - (03/18/02)
     
  274. Kidney failure in Women with HIV - (02/21/02)
     
  275. HIV Therapy for Pregnant Women - (02/20/02)
     
  276. AIDS Experts Cite New Opportunities: women/minorities/pregnancy by Vanessa Palo- The Associated Press - (02/11/02)
     
  277. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women - (12/27/01)
     
  278. IMPACT OF PREGNANCIES, ORAL CONTRACEPTION AND MENOPAUSE ON LIVER FIBROSIS PROGRESSION IN WOMEN WITH CHRONIC HEPATITIS C - (12/03/01)
     
  279. Risk for Increased Heart Disease in 45-Year Old Women with HIV and Lipodystrophy - (11/01/01)
     
  280. Screening for Anal and Cervical Dysplasia in HIV-Infected Patients PDF - (10/11/2001)
     
  281. Discontinuation of primary Pneumocystis carinii prophylaxis after reconstitution of CD4 cell counts in HIV-infected children - (9/14/01)
     
  282. Preventing disease by protecting the cervix: the unexplored promise of
    internal vaginal barrier devices
     (with PDF attached) - (9/20/01)
     
  283. Mother-to-Infant Transmission of Hepatitis C Virus - with full version in PDF format - (9/14/01)
     
  284. Gynecologic Problems for Women with HIV - in PDF format only from A Guide to the Clinical Care of Women with HIV - (9/10/01)
     
  285. Italian Study Finds HIV Delays Sexual Maturation in Boys & Girls Infected by their Mothers - (8/27/01)
     
  286. Gender Differences in Morphologic Alterations (Body Changes or Lipodystrophy) - (8/27/01)
     
  287. Mother-to-Child Transmission - (8/27/01)
     
  288. Role of HAART in Development of Hypertension Among HIV-Infected Women - (8/27/01)
     
  289. Access to Care for Women - (8/27/01)
     
  290. HPV Infection in Women and Men - Written for NATAP by Danielle Milano, MD - (8/2/01)
     
  291. HCV & Pregnancy, risk factors for transmission: breastfeeding, c-section, use of forceps in delivery - (8/1/01)
     
  292. Prevalence and Risk Factors for Anal Squamous Intraepithelial Lesions in Women - (6/15/2001)
     
  293. Immune Suppression and the Risk for Cervical Dysplasia - (5/15/2001)
     
  294. Women in HIV: - Highlights from the 8th Annual Retrovirus Conference (in simpler easier-to-read version)
    Written for NATAP by Kathleen Squires, MD, edited by Jules Levin, NATAP (3/07/2001)
     
  295. HIV Infection in Women - Reported for NATAP by Kathleen Squires, MD - (3/5/2001)
     
  296. Selected Highlights on HIV Transmission, Women & Children: HAART reduces perinatal transmission - (2/19/2001)
     
  297. Transmission From Mother to Newborn is Preventable if Viral Load is <1000 copies/ml at Delivery (1%) - (2/19/2001)
     
  298. HAART has a beneficial effect for women with HIV with Cervical Intraepithelial Neoplasia (CIN) - (2/19/2001)
     
  299. Women and Children Get HIV Also! - by Judith A. Aberg, M.D
     
  300. Women and Clinical Trials
     
  301. The HIV-Positive Woman: Are You Getting Good Medical Care? - by Debra Johnson, NP, PA-C and Kathleen E. Squires, MD - (2/16/2001)